Carl June

Aug 5, 2024 | nature.com | Georg Schett |Fabian Müller |Wei Qing Wang |Franco Locatelli |Carl June

AbstractChimeric antigen receptor (CAR) T cells are highly effective at targeting and eliminating cells of the B cell lineage. CAR T cell therapy has become a standard-of-care treatment for patients with relapsed or refractory B cell malignancies. In addition, the administration of genetically modified T cells with the capacity to deplete B cells and/or plasma cells has tremendous therapeutic potential in autoimmune diseases.

Jun 8, 2024 | cell.com | Regina Young |Carl June

HighlightsThe efficacy of chimeric antigen receptor (CAR) T cells targeting solid tumors is constrained by target heterogeneity, treatment-associated toxicities, and immunosuppressive factors in the tumor microenvironment, such as poor T cell infiltration, metabolic stress, and T cell exhaustion. Toxicities associated with CAR T cell therapies can limit administration of therapeutic doses of CAR T cells.

Mar 13, 2024 | nature.com | Stephen J. Bagley |Meghan T. Logun |Julie K. Jadlowsky |Fang Chen |MacLean P. Nasrallah |Wei-Ting Hwang | +5 more

AbstractRecurrent glioblastoma (rGBM) remains a major unmet medical need, with a median overall survival of less than 1 year. Here we report the first six patients with rGBM treated in a phase 1 trial of intrathecally delivered bivalent chimeric antigen receptor (CAR) T cells targeting epidermal growth factor receptor (EGFR) and interleukin-13 receptor alpha 2 (IL13Rα2). The study’s primary endpoints were safety and determination of the maximum tolerated dose.